

1 **Non-communicable diseases Prevalence by HIV Status in East Africa: A protocol**  
2 **for a systematic review and Meta-analysis.**

3 Asani Kasango<sup>1</sup> Alex Daama<sup>1,2</sup> Lilian Negesa<sup>1</sup>

4 <sup>1</sup> Rakai Health sciences program

5 <sup>2</sup>African Medical and Behavioral Sciences Organization

6 AK: [hassankasango25@gmail.com](mailto:hassankasango25@gmail.com)

7 AD: [daamaalex6141@gmail.com](mailto:daamaalex6141@gmail.com)

8 LN: [liliannegesa@gmail.com](mailto:liliannegesa@gmail.com)

9

10 **Corresponding author: Asani Kasango. Rakai Health Sciences Program (RHSP). P.O Box 179,**

11 **Kalisizo. Mobile phone: +256757980414 Email: [hassankasango25@gmail.com](mailto:hassankasango25@gmail.com)**

12

13

14

15

16

17

18

19

## 20 Abstract

21 **Introduction:** Over the past decade, HIV care and treatment programs have grown exponentially,  
22 resulting in improved survival among persons living with HIV. In the same period, the prevalence of non-  
23 communicable diseases has been reported to be higher among people living with HIV as compared to their  
24 HIV-negative counterparts. In this review, we aim to assess the prevalence of non-communicable diseases  
25 stratified by HIV status in East Africa.

26 **Methods:** We plan to assess observational studies especially case-control, cohort, and cross-sectional  
27 studies and clinical trials. These studies will be related to non-communicable diseases and done in East  
28 Africa. This review will be for studies done in East Africa from 1<sup>st</sup> Jan 2013 to 31<sup>st</sup> Dec 2023. The team  
29 will search databases such as East African Medical Journal, PubMed, Pan African Medical Journal,  
30 Scopus, African Health Sciences Journal, African Index, Medicus, and African Journals Online among  
31 others. We will use subheadings such as HIV, NCDs, and East Africa to search for relevant Journals.  
32 The  $I^2$  will be used to assess the heterogeneity of individual studies. All statistical analyses will be  
33 performed in STATA V15, and results will be graphically presented on a forest plot.

34 **Discussion:** With the rising burden of non-communicable diseases globally, there is much to learn  
35 whether the prevalence differs by HIV status or not.

36 **Keywords:** HIV, non-communicable diseases (NCDs), prevalence, East Africa.

## 37 Introduction

38 HIV/AIDS is a priority public health concern that has existed for over 30 years. It has contributed to 75  
39 million cases and 32 million deaths (1). There has been a rapid increase in coverage of HIV care and  
40 treatment within the past decade (2). These programs have successfully controlled viremia and Acquired  
41 Immunodeficiency syndrome through ARVs (3). People living with HIV (PLHIV) are now aging and are  
42 now susceptible to non-communicable diseases (NCDs) (3,4).

43 NCDs account for 70% of global deaths per annum and since a significant proportion of PLHIV are aging,  
44 it's predicted that NCDs will become the leading cause of morbidity and mortality among PLHIV by 2030

45 (5). Non-communicable diseases are associated with increased morbidity and mortality in the general  
46 population and among PLHIV. For instance, a report from the global burden of diseases, injuries, and Risk  
47 Factor (GBD) study indicated a 40% increase in NCDs disability-adjusted life years (DALYs) between  
48 2007 and 2017, and NCDs alone contributed to 62% of DALYs in the same period (6). The growing  
49 burden of NCDs has necessitated the need to compare the NCD prevalence by HIV status to inform  
50 program managers and Health policymakers in East Africa to adopt, implement, and scale up appropriate  
51 interventions for most at-risk subpopulations for NCD screening and management.

## 52 **Aim:**

53 This review aims to systematically compare the prevalence of NCDs by HIV status in East Africa.

## 54 **Methods**

55 **Study design:** The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)  
56 guidelines (7) will be followed during the conduct of this systematic review and Meta-Analysis.

57 **Study setting:** The setting for the study will be studies on NCDs done from 1<sup>st</sup> Jan 2013-31<sup>st</sup> Dec 2023 in  
58 East Africa.

59 **Population:** Studies that assessed any NCDs will be included.

60 **Exposures of Interest:** Exposures of interest will be HIV, ART use, and traditional risk factors for NCDs  
61 such as overweight, obesity, alcohol use, smoking, excessive salt consumption, and unhealthy diets.

62 **Comparison:** We will compare NCD prevalence by HIV status.

63 **Outcome:** The outcome will be the prevalence of NCDs. The non-communicable diseases to be  
64 considered include hypertension (HT), type 2 diabetes (T2DM), mental illnesses, other coronary heart  
65 diseases, cancer, and kidney disease will be assessed.

66 **Time frame:** Studies on NCDs published from 1<sup>st</sup> January 2013 to 31<sup>st</sup> Dec 2023.

67

68 **Search strategy:**

69 A comprehensive search for eligible studies will be done using databases such as East African Medical  
70 Journal, PubMed, Pan African Medical Journal, Scopus, African Health Sciences Journal, African Index,  
71 Medicus, African Journals Online, and WHO databases among others. We will use subject headings to  
72 elicit studies. Furthermore, key terms will include HIV, NCDs, prevalence, and East Africa.

73 **Inclusion criteria:** The studies will be selected for inclusion using the PECOTS framework where; P is  
74 Population, E is exposure, C is Comparison, O is Outcome, T is Time frame and S is Study setting (8).  
75 We will additionally include cross-sectional, case-control, cohort studies, and clinical trials. Furthermore,  
76 only studies reported in English will be included in this review.

77 **Exclusion criteria:** We will exclude non-empirical, qualitative, and epidemiological studies that do not  
78 report measures of association including prevalence, incidence, odds ratios (ORs), and Hazard ratios  
79 (HRs).

80 **Study selection:** AK and LN will search for eligible studies. We will screen the title and abstract of  
81 retrieved articles using Microsoft Excel. The selected articles will be retrieved for data abstraction. Any  
82 disagreements that will emerge during data abstraction will be addressed by consulting the third author  
83 (AD). In case of unclear and or missing data, the corresponding authors of the primary studies will be  
84 emailed. If he/she does not respond after two weeks, he/she will be telephone contacted (if a phone is  
85 available and or reachable) and an email reminder will be sent. If no response is obtained after 1 week,  
86 the article will be removed and will be reported in the PRISMA flow diagram.

87 **Quality assessment:** To ensure quality assessment, the Newcastle-Ottawa Scale (NOS) will be used. A  
88 'star' structure will be used to score and assess the quality of studies. The maximum score for any study is  
89 8. Studies with a score  $\geq 5$  or higher will be considered high quality.

90 **Data extraction**

91 The following data will be extracted: author's details, participants' characteristics including their  
92 sociodemographic attributes, the year of article publication, study type, study setting, HIV status, study  
93 sample size, ART status, prevalence of NCDs, overweight, obesity and other risk factors for NCDs.

## 94 **Statistical Analysis**

95 Data analysis will be performed using STATA V15.0. Furthermore, random-effects meta-analysis will  
96 be employed to account for variability in the prevalence of different studies. We will use a binomial  
97 distribution model to predict prevalence estimates. We will then apply the Freeman-Turkey double  
98 arcsine to transform parameters. After normalizing the estimates, pooled estimates will be calculated.

99 The heterogeneity of studies will be assessed using Cochran's Q statistic (and this will be expressed  
100 using  $X^2$  and p-value). Additionally, we will perform the  $I^2$  statistic. The sources of heterogeneity will  
101 be explored through subgroup analyses and by performing meta-regression analysis. The study design,  
102 sample size, methodology quality, and the year of publication will be assessed using univariate meta-  
103 regression models. Sensitivity analysis will also be performed to investigate if the results are influenced  
104 by a single study. We will present pooled estimates to account for heterogeneity.

### 105 **Anticipating limitations and bias:**

106 The authors recognize that there will be limitations to this review. The major limitation of this review is  
107 publication bias. This will be ascertained by conducting a sensitivity analysis. By doing this, we will  
108 determine each study status by how it graphically fits on the funnel plot. On the funnel plot, studies with  
109 high precision tend to plot closer to the mean while those whose precision is low disperse away from the  
110 mean. We will further use Egger and Begg's test to ascertain publication bias. Any p-value  $< 0.1$  will  
111 indicate publication bias.

## 112 **Discussion**

113 We plan to summarize the totality of evidence on the prevalence of NCDs by HIV status in East Africa.  
114 Findings may in part be useful in identifying further research priorities to address these gaps and to support  
115 a better understanding of the burden of NCDs in the region.

### 116 **Strengths and Limitations:**

117 This will be a meta-analysis of studies done in East Africa and will provide a better prevalence of NCDs  
118 by HIV status. It is also one of the few reviews in East Africa to stratify NCD prevalence by HIV status,  
119 making its results more generalizable compared to individual studies. The key limitation of this review is

120 that it will only include studies done in English. Furthermore, this review will be limited by publication  
121 bias.

## 122 **Conclusion**

123 In conclusion, a review such as this could help to inform the world about the prevalence of non-  
124 communicable diseases by HIV status in Africa.

## 125 **Declarations**

### 126 **Ethics approval and consent to participate:**

127 Not applicable

### 128 **Consent for publication:**

129 Not Applicable

### 130 **Availability of Data and Methods**

131 Data sharing does not apply to this article as no datasets were generated or analyzed during the current  
132 study.

### 133 **Compelling interests:**

134 We declare no conflict of interest.

### 135 **Funding:**

136 This study was funded by individual authors as no external support was used.

### 137 **Authors' contributions**

138 AK conducted the pre-research, designed the review, developed the search strategy, and drafted the  
139 manuscript; LN provided input on the design, developed the search strategy, and edited the manuscript;  
140 All authors reviewed and approved the final manuscript.

### 141 **Acknowledgements:**

142 We acknowledge the principal investigators for the primary studies for sacrificing resources, time, and  
143 effort for the different studies. We equally acknowledge the research assistants and study participants in  
144 the primary studies.

## 145 **References**

- 146 1. Lozada JS. Joint United Nations Programme on HIV/AIDS. *Encycl Glob Heal*. 2012;
- 147 2. Ataro Z, Ashenafi W, Fayera J, Abdosh T. Magnitude and associated factors of diabetes mellitus  
148 and hypertension among adult HIV-positive individuals receiving highly active antiretroviral  
149 therapy at Jugal Hospital, Harar, Ethiopia. *HIV/AIDS - Res Palliat Care*. 2018;10:181–92.
- 150 3. Venkat Narayan KM, Miotti PG, Anand NP, Kline LM, Harmston C, Gulakowski R, et al. HIV  
151 and noncommunicable disease comorbidities in the era of antiretroviral therapy: A vital agenda  
152 for research in low-and middle-income country settings. *J Acquir Immune Defic Syndr*.  
153 2014;67(SUPPL.1):2–7.
- 154 4. Wang T, Yi R, Green LA, Chelvanambi S, Seimetz M, Clauss M. Increased cardiovascular  
155 disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat.  
156 *Cardiovasc Pathol*. 2015;24(5):279–82.
- 157 5. World Health Organization. Global mortality from Non-communicable diseases. 2020;
- 158 6. Global Burden of Disease. Global, regional, and national disability-adjusted life-years ( DALYs )  
159 for 359 diseases and injuries and healthy life expectancy ( HALE ) for 195 countries and  
160 territories, 1990 – 2017 : a systematic analysis for the Global Burden of Disease Study 201.  
161 *Lancet*. 2019;1990–2017.
- 162 7. Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA  
163 2020 statement : an updated guideline for reporting systematic reviews. *BMC Syst Rev*. 2021;1–  
164 11.
- 165 8. Oladimeji KE, Dzomba A, Adetokunboh O, Zungu L, Yaya S, Goon D Ter. Epidemiology of  
166 multimorbidity among Saharan people living with HIV in sub- - Africa : a systematic review

167 protocol. 2020;1–6.

168

169

170